Among the promising targets are the epidermal growth factor receptor (EGFR) and the mesenchymal-epithelial transition factor (MET), both of which are frequently overexpressed or aberrantly activated in a range of cancers, including lung, breast, gastric, and glioblastoma.11,12 These receptors play critical roles in cell proliferation, survival, and metastasis. Here, MET is linked to cancer.